胶质母细胞瘤MR引导放疗中靶区早期体积动态:MARGA-I前瞻性试验初步结果
MARGA-I前瞻性单中心研究纳入25例胶质母细胞瘤患者,在0.35T MR-linac上于治疗前及每5次分次采集TrueFISP和T2-FLAIR图像,纵向分析扩展切除腔和FLAIR高信号体积变化。结果显示非增强MR-linac成像可可靠捕捉靶区体积动态,体积变化异质性大,早期和晚期均可出现重大变化,FLAIR轮廓在74%患者中超出CTV >1cc。
要点
- 非增强MR-linac成像与诊断MRI轮廓一致性高(Pearson r > 0.96)。
- 扩展切除腔重大增加/减少/轻微变化分别占59%/27%/14%,FLAIR轮廓为79%/0%/21%。
- FLAIR轮廓在74%患者中超出CTV >1cc,扩展切除腔超出CTV和95%等剂量线>1cc分别占27%和18%。
核心结论
- 非增强MR-linac成像可可靠捕捉胶质母细胞瘤放疗期间靶区体积动态变化。
- 体积变化在患者间异质性大,重大变化可在早期和晚期出现,支持系列成像用于个体化自适应放疗的进一步研究。
研究设计与样本
- 前瞻性单中心研究,纳入25例胶质母细胞瘤患者,在0.35T MR-linac上接受放疗。
- 治疗前及每第5次分次采集TrueFISP和T2-FLAIR图像,纵向勾画和分析扩展切除腔及FLAIR高信号体积。
主要发现
- MR-linac衍生轮廓与诊断MRI轮廓对应良好(Pearson r > 0.96)。
- 扩展切除腔重大增加、重大减少、轻微变化分别占59%、27%、14%;FLAIR轮廓分别占79%、0%、21%。
- 早期与晚期体积变化差异无统计学意义。
- FLAIR轮廓在74%患者中超出CTV >1cc;扩展切除腔超出CTV和95%等剂量线>1cc分别占27%和18%。
- 无临床或分子参数显著预测体积轨迹。
关键数值与推荐
- 体积变化>±10%定义为重大变化。
- FLAIR轮廓超出CTV >1cc见于74%患者;扩展切除腔超出CTV和95%等剂量线>1cc分别见于27%和18%患者。
临床怎么用
- 可考虑利用非增强MR-linac系列成像监测胶质母细胞瘤放疗中靶区体积变化。
- 体积变化异质性大且早期晚期均可发生重大变化,提示自适应放疗策略需个体化评估。
局限性
- 单中心前瞻性研究,样本量25例。
- 体积变化的临床意义尚未明确,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Serial MRI during radiotherapy may enable early response assessment and guide adaptive treatment strategies; however, data on intratreatment volumetric changes remain limited. We herein report results of the MARGA-I-study, investigating target volume changes during MR-linac-based radio-(chemo-)therapy. MATERIALS AND METHODS: In this prospective single-center-study, 25 patients with glioblastoma were treated on a 0.35-T-MR-linac. TrueFISP and T2-FLAIR images were acquired before treatment and every fifth fraction. TrueFISP-based extended resection cavity (cavity/tumor residue) and FLAIR-hyperintense volumes were contoured and analyzed longitudinally. Volume changes were stratified among early (SIM-f5) and late (f5-last fraction) phase and changes >±10% were deemed major. The exceedance of the volumes over the CTV and 95% isodose line was evaluated. RESULTS: Extended-resection-cavity- and FLAIR-contours derived from MR-linac imaging showed correspondence with those from diagnostic MRI (Pearson r > 0.96). In the extended resection cavity, 59%/27%/14% of analyzed patients showed major increase/major decrease/minor changes respectively. In FLAIR contours, the prevalences were 79%/0%/21% respectively. Differences between early and late volume changes were not statistically significant. The FLAIR contours exceeded CTV >1cc in 74% of patients, while the extended resection cavity exceeded the CTV and 95% isodose line >1cc in 27% and 18% respectively. No clinical or molecular parameter significantly predicted volumetric trajectories. CONCLUSION: Non-contrast MR-linac imaging reliably captures glioblastoma target volume dynamics during treatment. Volumetric changes are heterogeneous across patients and major changes can occur both early and late, underscoring the potential for serial imaging. Our data provide a rationale for further investigation of the clinical significance of these changes and their potential utility for individualized adaptive radiotherapy strategies.
引用
- Kretzschmar L, Wallimann P, Obergfell LM, et al. Early target volume dynamics during MR-guided radiotherapy for glioblastoma: first results from the prospective MARGA-I trial. Radiother Oncol. 2026. PMID: 42830173. doi:10.1016/j.radonc.2026.111792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。